Allianz Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Allianz Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-18,264	Closed	-$1.43M	–	2637
2015 Q1	$1.43M	Sell	18,264 -3,476	-16%	-$216K	﹤0.01%	1662
2014 Q4	$1.32M	Sell	21,740 -171	-0.8%	-$8.59K	﹤0.01%	1729
2014 Q3	$933K	Sell	21,911 -1,079	-5%	-$57.9K	﹤0.01%	1683
2014 Q2	$1.42M	Sell	22,990 -23,299	-50%	-$1.35M	﹤0.01%	1301
2014 Q1	$3.01M	Sell	46,289 -1,399	-3%	-$94.6K	﹤0.01%	1085
2013 Q4	$2.69M	Sell	47,688 -1,487	-3%	-$83.6K	﹤0.01%	1129
2013 Q3	$3.02M	Sell	49,175 -875	-2%	-$59.3K	﹤0.01%	1075
2013 Q2	$2.92M	Buy	+50,050	New	+$3.08M	﹤0.01%	1071

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allianz Asset Management's OREX Position: Q2 2015 in Review

Allianz Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 18,264 shares — an estimated $1.43M sold.

Allianz Asset Management first reported a position in OREX in Q2 2013 and held it in 8 quarters. The position peaked at $3.02M in Q3 2013. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

Allianz Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Allianz Asset Management sold 18,264 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $1.43M.
Allianz Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
Allianz Asset Management's Orexigen Therapeutics, Inc. position peaked at $3.02M in Q3 2013.
161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Allianz Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.